Researchers found that dexamethasone eye drops may reduce the risk that retinopathy of prematurity advances to the treatment stage. For babies born extremely early, abnormal blood vessel growth in the retina can threaten their sight before they leave the hospital. Researchers in Sweden have now completed the world’s first randomized clinical trial testing whether cortisone [...]In the realm of modern ophthalmology, Optical Coherence Tomography (OCT) has revolutionized the way eye diseases are diagnosed and monitored. This non-invasive imaging technology allows clinicians to peer through the layers of the retina, producing detailed cross-sectional images that reveal the structural integrity of this delicate tissue without the need for surgical intervention. However, despite OCT’s widespread adoption and profound clinical impact, the technology is inherently limited by physical constraints that occasionally obscure or degrade the crucial information contained within these images. The newly developed Spatio-Temporal Optical Coherence Tomography (STOC-T) promises to address these limitations by fundamentally altering data acquisition methods, thereby enhancing image quality and diagnostic precision at the earliest possible stage.
OCT functions by directing light into the eye and interpreting the backscattered photons to construct images of internal structures like the retina and choroid. But the journey of photons through tissue is fraught with challenges. When light encounters complex biological matrices, it scatters unpredictably, producing signals that blend with those carrying useful information. This phenomenon, known scientifically as “optical crosstalk,” causes image blur and loss of contrast, making it difficult to discern fine detail that could be critical for early disease detection. Optical crosstalk is essentially a breakdown of coherence within the returning light, as photons from a single spatial point arrive dispersed across multiple detector pixels. For ophthalmologists and patients alike, this translates to potentially missed or delayed diagnosis of conditions where subtle changes herald disease onset.
The breakthrough reported by Professor Maciej Wojtkowski and his team from the International Centre for Translational Eye Research (ICTER) introduces STOC-T, an innovative approach that goes beyond conventional image enhancement techniques. Unlike software filters applied post-hoc to clean up images, STOC-T reforms the optics of data collection itself—imposing controlled, repetitive phase modulations onto the illuminating light during scanning. By employing distinct spatial phase masks that alter the wavefront of the illuminating beam, the system captures a series of images, each with a differently patterned illumination. Scattered photons, which respond chaotically to these phase shifts, become decorrelated and diminish upon averaging multiple frames. Conversely, photons faithfully reflecting true tissue architecture maintain coherent behavior, thus strengthening their visibility in the final reconstructed image.
This methodology can be likened to differentiating a single voice in a bustling crowd. Just as a consistent voice can be isolated amid random background chatter using adaptive recording strategies, STOC-T distinguishes meaningful optical signals from noise in real-time. This preemptive discrimination obviates the need for computational post-processing to “clean” images after data acquisition, which historically cannot fully recover information lost to scattering. Defensive design of the imaging process ensures that interfering signals are suppressed from the outset, preserving delicate cellular-level details of the retina and choroid that are indispensable for early diagnosis.
STOC-T’s performance has been rigorously tested both in laboratory settings and on living tissue. In one compelling demonstration, a standard imaging target obscured by a highly scattering artificial medium and even by rat skin rendered virtually invisible under conventional OCT. Upon integrating STOC-T’s phase modulation technique, the obscured structural features resurfaced with remarkable clarity. This experiment underscores the scale of the optical crosstalk problem and the potency of STOC-T, since the objects remained physically present but were previously hidden by noise.
The true clinical significance comes from STOC-T’s application to human retinal imaging, where it achieves a lateral resolution near five micrometers—a scale sufficiently fine to resolve individual photoreceptors and ganglion cells as well as intricate vasculature within the choroid. This extraordinary level of detail enables prospective monitoring of microscopic disease processes with an acuity far surpassing existing OCT methods. Additionally, STOC-T provides new insights through optoretinography (ORG), capturing functional responses of photoreceptors to flickering light stimuli at frequencies up to 45 Hz. These functional measurements resemble electrophysiological studies conducted via invasive patch-clamp techniques, suggesting that STOC-T could non-invasively monitor cellular function—a significant leap for early detection of retinal dysfunction before structural damage occurs.
The potential clinical impact of this technology cannot be overstated. Visual impairment affects more than 2.2 billion individuals worldwide, with over a billion cases attributable to conditions amenable to early diagnosis and intervention. Diseases such as glaucoma, diabetic retinopathy, and age-related macular degeneration often become irreversibly severe due to delayed detection. STOC-T’s capacity to enhance diagnostic accuracy at the cellular and functional levels augments the ophthalmologist’s ability to initiate timely therapies, potentially halting or reversing vision loss before clinical symptoms manifest.
Despite these promises, STOC-T remains an experimental technique, currently limited by technical demands. The system requires cutting-edge hardware, including a high-speed CMOS camera capable of capturing quarter-million frames per second and a tunable near-infrared laser source spanning 800 to 870 nanometers in wavelength. The immense data volume generated—exceeding 8.5 gigabytes per acquisition—also presents significant computational challenges for real-time processing and analysis. These hurdles explain why STOC-T is not yet in widespread clinical use, although ongoing advances in photonic hardware and data science are likely to mitigate these barriers.
Looking forward, the research team envisions enhancing the system’s flexibility using multimode optical fibers for phase modulation. Such fibers, with diameters around 50 micrometers and lengths extending to hundreds of meters, support hundreds of propagation modes. They offer the theoretical potential to reduce optical crosstalk noise by a factor approaching 30 without complex electronic controls, simplifying implementation while preserving image quality improvements.
Professor Wojtkowski emphasizes that STOC-T represents a transformative conceptual advance rather than a final product. The roadmap to widespread application involves optimizing speed, minimizing data volume, refining phase encoding strategies, and automating image reconstruction workflows. The foundational principle—shaping the acquisition process to preempt noise contamination—opens avenues not only for ophthalmology but also for diverse biomedical imaging fields where light scattering impairs image fidelity. This innovation exemplifies how deep physical understanding combined with technical ingenuity can reshape diagnostic imaging, making previously invisible biological details accessible and advancing patient care.
In summary, STOC-T addresses a critical bottleneck in OCT imaging by employing spatio-temporal phase modulation to separate meaningful tissue signals from scattered noise at the data collection stage. This technique enhances resolution, contrast, and functional imaging capability, holding significant promise for earlier and more accurate diagnosis of a broad spectrum of vision-threatening diseases. Although currently laboratory-bound due to technical demands, STOC-T’s theoretical and experimental foundations herald a new era in optical imaging, where noise is never blindly accepted but actively prevented from degrading our view of living tissue.
Subject of Research: Human tissue samples
Article Title: Spatio-temporal optical coherence imaging and tomography for in vivo applications
News Publication Date: 25-May-2026
Web References: DOI: 10.1117/1.JBO.31.11.113504
Image Credits: Optica
Optical coherence tomography, STOC-T, ophthalmology, retinal imaging, optical crosstalk, phase modulation, optoretinography, photoreceptors, biomedical optics, imaging noise reduction, high-resolution microscopy, optical imaging innovations
A Yale-led study uncovered unexpected communication between retinal visual pathways that were thought to operate separately. Researchers at Yale School of Medicine (YSM) have discovered unexpected insights into how the eye handles visual information. When we view a scene, the visual system quickly separates different features, including color, contrast, and motion, and processes them independently. [...]Often hailed as “the window to the soul,” the human eye has long fascinated scientists and philosophers alike. However, beyond its poetic allure, emerging research suggests that the eyes provide a vital window into the health of the brain. A groundbreaking new study spearheaded by the University of Florida’s biomedical engineering department has unveiled a transformative approach to predicting Alzheimer’s disease risk factors by analyzing retinal photographs with cutting-edge deep learning algorithms. This development promises to revolutionize early detection and intervention for one of the most devastating neurodegenerative diseases.
Traditionally, diagnosing Alzheimer’s disease has been a challenge due to its insidious onset and prolonged development over decades. Most diagnostic protocols focus on detecting the disease in its later stages, by which time significant, irreversible brain damage has already occurred. Recognizing this limitation, Dr. Ruogu Fang and her interdisciplinary team leveraged advances in artificial intelligence and biomedicine to explore the retina—a part of the central nervous system accessible via non-invasive imaging—as a potential biosensor for Alzheimer’s risk.
The study capitalized on a rich database of over 40,000 retinal images collected from the UK Biobank, a comprehensive health resource with longitudinal patient data. Retinal photography is commonly conducted during routine eye exams, diabetes management, glaucoma monitoring, and cataract assessments. By harnessing these widely available, inexpensive images, the research team circumvented the need for costly, invasive, or logistically complex diagnostic tools such as MRI or PET scans, thus holding promise for scalable, population-wide screening.
Employing deep learning, a subset of machine learning characterized by neural networks modeled after the human brain, the researchers developed an AI framework that scrutinized retinal morphology. This model was able to discern subtle variations in retinal arteries, veins, and the optic nerve head, features imperceptible to the human eye but correlated strongly with known risk factors for Alzheimer’s disease. Such morphological markers serve as proxies for neurovascular health, which is crucial given Alzheimer’s recognized association with vascular impairment.
One of the most striking revelations of this research was the model’s capacity not only to predict intrinsic biological traits such as sex and blood pressure but also modifiable lifestyle factors that influence Alzheimer’s risk. The AI effectively inferred behaviors like smoking, alcohol consumption, and even insomnia from retinal images alone. This objective measurement circumvents the notorious unreliability of self-reported lifestyle data, often plagued by bias and inaccuracies, thereby enriching risk assessment precision.
As Dr. Fang points out, retinal morphology functions less like a mere clinical questionnaire and more like an integrative biological sensor reflecting a cumulative lifetime burden of neurovascular and lifestyle insults. This conceptual shift underscores the retina’s role in encapsulating decades of physiological data, transforming retinal imaging into a powerful tool for capturing both present health and future vulnerability.
Furthermore, the implications extend beyond risk prediction. Identifying individuals with early signs of retinal changes could trigger timely clinical interventions long before cognitive symptoms manifest. Such preclinical detection enables the implementation of protective lifestyle adjustments, pharmacological therapies, or cognitive training programs designed to delay or mitigate Alzheimer’s progression.
The pioneering work built on previous findings from Fang’s group that demonstrated retinal images’ utility in detecting active Alzheimer’s disease cases. However, this new model pioneers the field by focusing on prodromal markers and risk factors instead of established dementia, bridging a critical gap in neurodegenerative diagnostics.
Importantly, the use of retinal photographs democratizes neurovascular health monitoring. Since retinal imaging is non-invasive, accessible, and affordable, it offers the prospect of integrating brain health assessment into routine eye care, thus expanding preventive neurology beyond specialized clinical settings.
This research also exemplifies the synergy between computational science and biomedical engineering. By combining sophisticated image analysis algorithms with large-scale patient data, it transcends traditional diagnostic constraints, marrying technology with medicine in a profoundly impactful manner.
While challenges remain, including the need for further validation across diverse populations and integration with other biomarkers, this study sets a new paradigm for early Alzheimer’s disease risk stratification. The possibility of preemptive interventions guided by retinal AI analysis heralds a future where the devastating trajectory of Alzheimer’s may be altered through timely and personalized healthcare.
In summary, the novel application of deep learning to retinal photographs opens an unprecedented window into brain health, heralding a new era of precision neurodiagnostics. It moves us closer to the long-sought goal of identifying Alzheimer’s risk decades in advance, fostering opportunities for early intervention and ultimately, better patient outcomes.
Subject of Research: People
Article Title: Prediction of Alzheimer’s disease risk factors from retinal images via deep learning: Development and validation of biologically relevant morphological associations in the UK Biobank
News Publication Date: 16-Jun-2026
Web References:
DOI: 10.1177/13872877261457650
Alzheimer’s disease, Neurodegenerative diseases, Neurological disorders, Eye, Retina, Artificial intelligence, Image analysis, Deep learning, Biomedical engineering, Neurovascular integrity, Retinal biomarkers, Predictive modeling
In a groundbreaking advancement for ocular science, a multidisciplinary research team from the University of Minnesota Medical School has embarked on a four-year investigative journey funded by a substantial $2.2 million grant from the National Eye Institute. This highly anticipated project aims to elucidate the intricate molecular foundations of retinal diseases, particularly focusing on age-related macular degeneration (AMD) and the uncommon but debilitating Doyne honeycomb retinal dystrophy, also known as Malattia Leventinese (DHRD/ML). By leveraging cutting-edge approaches in molecular biology and ophthalmologic research, the team aspires to pioneer transformative therapies that address the multifaceted challenges posed by these degenerative eye conditions.
Central to this research initiative is the exploration of extracellular matrix proteins, a class of biomolecules that form the structural and functional scaffolding outside cells. Of particular interest within this complex microenvironment is fibulin-3, an extracellular matrix glycoprotein implicated in maintaining the integrity and homeostasis of retinal tissues. Mutations and alterations in the fibroblast-derived fibulin-3 have been identified as key contributors to the pathogenesis of various blinding disorders, positioning this protein at the forefront of retinal disease research. Understanding fibulin-3’s biological role and its dysregulation promises to unlock novel therapeutic avenues for preventing vision loss.
Professor John Hulleman, PhD, an esteemed ophthalmology and visual neurosciences researcher at the University of Minnesota Medical School, emphasizes the significance of this endeavor. He remarks that the project not only intensifies the focus on fibulin-3’s molecular dynamics but also strives to develop sophisticated tools to dissect its functional interactions within the retinal extracellular matrix. This approach underscores a shift towards targeting the extracellular matrix environment itself, rather than solely focusing on intra-cellular pathways, thus broadening the horizon for innovative treatment modalities.
Age-related macular degeneration, a leading cause of irreversible vision loss among the elderly, is characterized by progressive degeneration of the macula, the central region of the retina responsible for sharp, central vision. Current therapies, while somewhat effective in managing symptoms, often fail to halt or reverse the underlying pathology. The research spearheaded by the University of Minnesota seeks to transcend these limitations by identifying molecular targets within the extracellular matrix that mediate AMD progression, which could lead to breakthrough treatments with enhanced efficacy.
Alongside AMD, the project addresses Doyne honeycomb retinal dystrophy, a rare congenital disorder exhibiting clinical and pathological overlap with AMD. DHRD/ML is marked by the deposition of abnormal extracellular materials within the retina, leading to impaired photoreceptor function and progressive vision deterioration. Dissecting the mechanistic pathways governing extracellular matrix remodeling in DHRD/ML through the lens of fibulin-3 aberrations provides a unique opportunity to develop targeted interventions that can ameliorate or even prevent the disease’s progression.
The research team will undertake a comprehensive pharmacological screening of existing FDA-approved drugs with the objective of repurposing them to mitigate AMD symptoms. This strategy leverages the pharmacokinetic profiles and safety data of known medications, potentially accelerating the timeline for clinical application. Simultaneously, the investigation will delve into the biological mechanisms regulating the synthesis, assembly, and degradation of retinal extracellular matrix proteins, aiming to delineate the homeostatic balances integral to healthy retinal function.
A significant aspect of the study involves characterizing the cellular pathways that control fibulin-3 expression and turnover, which are pivotal in maintaining extracellular matrix stability. Disruptions in these processes can lead to pathological accumulation or deficiency of critical matrix components, contributing to disease pathology. By elucidating these control mechanisms, the team aims to identify molecular checkpoints amenable to therapeutic modulation.
To facilitate these objectives, the researchers employ an array of sophisticated methodologies, including advanced imaging techniques, proteomic analyses, and in vitro cellular models that recapitulate retinal architecture and extracellular matrix interactions. These technologies enable high-resolution tracking of protein dynamics and intercellular communication in both normal and diseased states, generating critical insights into retinal degeneration.
Moreover, the initiative recognizes the intricate interplay between genetic predispositions and environmental factors in retinal disease etiology. Investigations into how fibulin-3 mutations influence extracellular matrix composition under various physiological conditions will enhance understanding of disease variability and patient-specific responses. This knowledge is essential for the future development of personalized medicine approaches tailored to individual molecular profiles.
The translational potential of this project is fortified by its dual approach, combining fundamental scientific inquiry with a pragmatic search for viable therapeutics. The anticipated outcomes include the generation of novel diagnostic biomarkers and the formulation of innovative treatment protocols that could significantly improve patients’ quality of life. This work exemplifies the integration of biomedical research with clinical imperatives, embodying a future where vision preservation is attainable.
Currently active under grant number 2R01EY027785-07A1, this endeavor not only epitomizes the University of Minnesota Medical School’s commitment to scientific excellence but also signifies a beacon of hope for millions affected by retinal degenerative diseases worldwide. Through rigorous investigation and cutting-edge technology, the research team is poised to reshape the landscape of vision science and ocular therapeutics.
As the study progresses, continuous updates and detailed findings are expected to stimulate further scientific inquiry and collaborative efforts across the biomedical community. The potential to bridge gaps between molecular understanding and clinical innovation positions this project as a landmark in the quest to combat retinal blindness.
Subject of Research: Molecular mechanisms and therapeutic development targeting extracellular matrix protein fibulin-3 in retinal diseases including age-related macular degeneration and Doyne honeycomb retinal dystrophy.
Article Title: University of Minnesota Researchers Secure $2.2M NIH Grant to Target Fibulin-3 in Retinal Disorders
News Publication Date: June 16, 2026
Web References:
https://med.umn.edu/bio/john-hulleman-phd
https://med.umn.edu/
Keywords:
Retinal diseases, Age-related macular degeneration, Doyne honeycomb retinal dystrophy, Malattia Leventinese, Fibulin-3, Extracellular matrix, Ophthalmology, Visual neuroscience, Drug repurposing, Molecular biology, Retinopathy, Therapeutic development
A rare inflammatory condition linked to tattoos is appearing more often in Australia.
Login